Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

ALKS 51.39 +1.27 (2.53%)
price chart
Alkermes plc versus Intrexon Corporation Head to Head Compare
Intrexon Corporation has a higher fundamental rating then Alkermes plc which has an impact on the head-to-head comparison. The CML Star Rating is an objective, quantifiable measure of a company's operating and financial condition.
Geode Capital Management LLC Has $33208000 Position in Alkermes PLC (ALKS)
Alkermes PLC logo Geode Capital Management LLC boosted its position in shares of Alkermes PLC (NASDAQ:ALKS) by 6.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
Alkermes Plc (NASDAQ:ALKS) Updated Price Targets  FTSE News
Alkermes plc (NASDAQ:ALKS) Annual EBIT At $-224.301 Millions
For the fiscal ended 2015-12-31, Alkermes plc (NASDAQ:ALKS) comprehensive income was $-3.795 millions. It was $-3.795 millions for the quarter closed 2015-12-31.
The Impact Score of Alkermes plc (NASDAQ:ALKS) Is 79
As such, based on its algorithm-based analytics, Alpha One has given Alkermes plc (NASDAQ:ALKS) daily sentiment score of 0.31.
Alkermes plc (NASDAQ:ALKS) Upcoming Earnings: What matter for investors?
Alkermes plc (NASDAQ:ALKS) increased 1.69% to reach at the trading price of $49.8 as it is set to share its next quarterly earnings on July 28, 2016.
Earnings Reaction History: Alkermes plc (NASDAQ:ALKS) has a 53.85% chance to ...  Zergwatch
How Analysts Feel About Alkermes Plc (NASDAQ:ALKS)?  Consumer Eagle
Alkermes plc Realized Volatility Hits Extreme Level
This is a proprietary realized volatility rating created by Capital Market Laboratories (CMLviz) based on a large number of data interactions for Alkermes plc (NASDAQ:ALKS) . We examine the little used gem of daily stock volatilty over a 20-day and 30 ...
Barclays Maintains Alkermes Plc to Overweight with Price Target $65.00
Brokerage firm Barclays Maintains its rating on Alkermes Plc(NASDAQ:ALKS). In a research note issued to the investors, the brokerage major Raises the price-target to $65.00 per share.
Equity Roundup: Stock Performance Focus on Alkermes plc (NASDAQ:ALKS)
During the most recent trading session, shares of Alkermes plc (NASDAQ:ALKS) changed +1.69%. Street analysts that track the company are anticipating the stock to go to $48.09 within the next year.
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2015 and ...
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases.
Alkermes Plc (ALKS) Richard F. Pops on Q4 2015 Results - Earnings Call ...  Seeking Alpha
Alkermes Q4 Loss Narrower than Expected, Updates Pipeline  Zacks.com
Alkermes PLC (NASDAQ:ALKS) Receives Average Rating of "Hold" from Analysts
Alkermes PLC logo Alkermes PLC (NASDAQ:ALKS) has received an average recommendation of “Hold” from the twelve brokerages that are covering the firm.
Alkermes Plc Ord (NASDAQ:ALKS) Sellers Covered 12.81% of Their Shorts  Consumer Eagle